• Most Popular
  • Most Shared

Neurochem shifts focus on Alzheimer's treatment

Thu Nov 8, 2007 7:28am EST

TORONTO, Nov 8 (Reuters) - Neurochem said on Thursday it planned to ramp up development of its key Alzheimer's disease treatment NRM-8499 and terminate European trials of its tramiprosate Alzheimer's treatment as it shifts its focus on the fight with the disease.

The company also said it planned to commercialize tramiprosate as a branded nutraceutical product starting as early as 2008 with the creation of a new self-sustaining company. ($1=$0.93 Canadian) (Reporting by Scott Anderson; Editing by Ka Yan Ng)



More from Reuters

Photo

Obama blames "systemic failures" in U.S. security

KANEOHE, Hawaii (Reuters) - President Barack Obama Tuesday blamed a combination of "human and systemic failures" for allowing the botched Christmas Day attack aboard a Detroit-bound U.S. airliner, in his first big test on homeland security. | Video

» More Top News
Leaves gather in front of an empty and boarded-up house in Youngstown, Ohio November 21, 2009. REUTERS/Brian Snyder

Castles built on sand

Rust-belt American cities like Youngstown, Ohio were battered by the downturn. Now they're ready to move on, but it won’t be easy. The first in a three-part report.  Full Article 

Route to Recovery
REUTERS/James Saft
JAMES SAFT:

Welcome to the "Teenies"

Shrinking financial sector? Paltry investment returns? Welcome to the the next decade. Don't worry, there's some good news, too.  Commentary 

COMMENTARY